Ventavia Research Group
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Manning, Erin L
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Shepard, Julie
NCT05084508 / 2022-001910-21: A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed
2
800
Europe, US, RoW
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
GlaxoSmithKline, GlaxoSmithKline Biologicals SA (GSK)
Chickenpox
02/24
06/24
NCT05630846: A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Completed
2
801
Europe, US, RoW
Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine, ProQuad
GlaxoSmithKline
Measles; Mumps; Rubella; Chickenpox, Measles
06/24
10/24
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting
2
800
US
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20
Vaxcyte, Inc.
Pneumococcal Vaccines
06/27
06/27
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Ondrizek, Richard R
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
Baird, Tiffany
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Recruiting
3
412
Europe, Canada, US, RoW
Salbutamol HFA-134a, Salbutamol HFA-152a
GlaxoSmithKline
Asthma
09/25
09/25
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Active, not recruiting
3
440
US
Infant Formula
Aussie Bubs, Inc.
Infant Development
04/25
04/25
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Muniz-Pujalt, Gysella
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Manning, Erin L
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Shepard, Julie
NCT05084508 / 2022-001910-21: A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed
2
800
Europe, US, RoW
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
GlaxoSmithKline, GlaxoSmithKline Biologicals SA (GSK)
Chickenpox
02/24
06/24
NCT05630846: A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Completed
2
801
Europe, US, RoW
Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine, ProQuad
GlaxoSmithKline
Measles; Mumps; Rubella; Chickenpox, Measles
06/24
10/24
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Recruiting
2
800
US
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20
Vaxcyte, Inc.
Pneumococcal Vaccines
06/27
06/27
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Ondrizek, Richard R
NCT05264506: Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Terminated
3
2007
US
NOMAC-E2 COC, Nomegestrol acetate / estradiol
Organon and Co, IQVIA Inc., OSTAtistics
Contraception
01/24
01/24
Baird, Tiffany
NCT06261957: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

Recruiting
3
412
Europe, Canada, US, RoW
Salbutamol HFA-134a, Salbutamol HFA-152a
GlaxoSmithKline
Asthma
09/25
09/25
NCT05947084: Comparison of Growth and Tolerance of Healthy Term Infants Fed Iron-Fortified Infant Formulas

Active, not recruiting
3
440
US
Infant Formula
Aussie Bubs, Inc.
Infant Development
04/25
04/25
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25
Muniz-Pujalt, Gysella
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Active, not recruiting
2
802
US
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Vaxcyte, Inc.
Pneumococcal Vaccines
12/25
12/25

Download Options